These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3366451)

  • 1. The ratio of prostate chips with cancer: a new measure of tumor extent and its relationship to grade and prognosis.
    Humphrey P; Vollmer RT
    Hum Pathol; 1988 Apr; 19(4):411-8. PubMed ID: 3366451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup.
    Epstein JI; Carmichael M; Partin AW; Walsh PC
    J Urol; 1993 Jun; 149(6):1478-81. PubMed ID: 8501792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraglandular tumor extent and prognosis in prostatic carcinoma: application of a grid method to prostatectomy specimens.
    Humphrey PA; Vollmer RT
    Hum Pathol; 1990 Aug; 21(8):799-804. PubMed ID: 2387573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of cancer progression in T1a prostate adenocarcinoma.
    Cheng L; Bergstralh EJ; Scherer BG; Neumann RM; Blute ML; Zincke H; Bostwick DG
    Cancer; 1999 Mar; 85(6):1300-4. PubMed ID: 10189135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gleason score as predictor of clinicopathologic findings and biochemical (PSA) progression following radical prostatectomy.
    Guimaraes MS; Quintal MM; Meirelles LR; Magna LA; Ferreira U; Billis A
    Int Braz J Urol; 2008; 34(1):23-9. PubMed ID: 18341718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer.
    Wheeler TM; Dillioglugil O; Kattan MW; Arakawa A; Soh S; Suyama K; Ohori M; Scardino PT
    Hum Pathol; 1998 Aug; 29(8):856-62. PubMed ID: 9712429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gleason histologic grading of prostatic carcinoma. Correlations between biopsy and prostatectomy specimens.
    Mills SE; Fowler JE
    Cancer; 1986 Jan; 57(2):346-9. PubMed ID: 3942967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
    Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
    Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate needle biopsies: multiple variables are predictive of final tumor volume in radical prostatectomy specimens.
    Poulos CK; Daggy JK; Cheng L
    Cancer; 2004 Aug; 101(3):527-32. PubMed ID: 15274065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy.
    Abaza R; Diaz LK; Laskin WB; Pins MR
    J Urol; 2006 Dec; 176(6 Pt 1):2701-5. PubMed ID: 17085199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
    Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
    J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma.
    Hattab EM; Koch MO; Eble JN; Lin H; Cheng L
    J Urol; 2006 May; 175(5):1695-9; discussion 1699. PubMed ID: 16600733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
    Zagars GK; Pollack A; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
    Cheng L; Poulos CK; Pan CX; Jones TD; Daggy JK; Eble JN; Koch MO
    J Urol; 2005 Sep; 174(3):898-902. PubMed ID: 16093983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The predictive accuracy of staging transurethral resection of the prostate in the management of stage A cancer of the prostate: a comparative evaluation.
    Lowe BA; Barry JM
    J Urol; 1990 Jun; 143(6):1142-5. PubMed ID: 2342175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models.
    Quinn DI; Henshall SM; Haynes AM; Brenner PC; Kooner R; Golovsky D; Mathews J; O'Neill GF; Turner JJ; Delprado W; Finlayson JF; Sutherland RL; Grygiel JJ; Stricker PD
    J Clin Oncol; 2001 Aug; 19(16):3692-705. PubMed ID: 11504751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4.
    Lau WK; Blute ML; Bostwick DG; Weaver AL; Sebo TJ; Zincke H
    J Urol; 2001 Nov; 166(5):1692-7. PubMed ID: 11586204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presence of high grade tertiary Gleason pattern upgrades the Gleason sum score and is inversely associated with biochemical recurrence-free survival.
    Turker P; Bas E; Bozkurt S; Günlüsoy B; Sezgin A; Postacı H; Turkeri L
    Urol Oncol; 2013 Jan; 31(1):93-8. PubMed ID: 21316989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.